In the future, more clinical or real-world studies are still needed, especially localized studies targeting Chinese prostate cancer patients, to further clarify the direct efficacy differences of the second-generation AR antagonists in the treatment of mHSPC and improve the accuracy and applicability of economic assessment. Here, AR is linked to prostate cancer.